WASHINGTON – Whether it’s a silver bullet, a monumental disappointment, or an inch toward something resembling progress, the cannabis industry’s mixed public opinions about rescheduling remind us how much is at stake for stakeholders, especially in areas that impact far more than the balance sheet.
After months of rumors and speculation about the decision, on Thursday the Department of Justice (DOJ) proposed moving cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). Rescheduling is expected to bring tax relief and other financial benefits to cannabis businesses and their hundreds of thousands of American workers. While many in the often financially challenging industry are celebrating the big news, others are far from satisfied with the major gaps between state and federal drug policy.
Industry Stakeholder Comment on Cannabis Rescheduling Proposal (mgmagazine.com)
